Discovering Resmetirom: A Selective Thyroid Hormone Receptor Beta Agonist in Phase 3 Clinical Development for the Treatment of NASH

Time: 1:30 pm
day: Day 1 Stream 3 PM


• Resmetirom development: The MAESTRO Phase 3 trials, multinational, double-blind, randomized, placebo-controlled clinical trial of resmetirom in patients with NASH and liver fibrosis
• Outlining the challenges with NASH trials
• Hearing how to create a foolproof plan to successfully recruit patients for NASH clinical trials